Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Zhong-Ping Duan"'
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background Thermal therapy induces an immune response in patients with hepatocellular carcinoma (HCC), but the dynamic characteristics of the natural killer (NK) cell immune response post-thermal ablation remain unclear. We conducted a prosp
Externí odkaz:
https://doaj.org/article/a57eed75e0244a0db373a8c43153a032
Autor:
Hai-Yan Wang, Xiong-Wei Cui, Yong-Hong Zhang, Yu Chen, Ning-Ning Lu, Shou-Peng Sheng, Wen-Feng Gao, Xiao-Zheng Yang, Zhong-Ping Duan
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundTopical therapy has been shown to induce an immune response in patients with hepatocellular carcinoma (HCC). In this study, a prospective parallel group control experiment was conducted to compare the differences between radiofrequency abla
Externí odkaz:
https://doaj.org/article/8c45202c12d84fe2a18f802f4e0adcb0
Autor:
Ting Wang, Xue-ying Huang, Su-jun Zheng, Ye-ying Liu, Si-si Chen, Feng Ren, Jun Lu, Zhong-ping Duan, Mei Liu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Hepatocellular carcinoma (HCC) is a common malignancy worldwide. Alpha-fetoprotein (AFP) is still the only serum biomarker widely used in clinical settings. However, approximately 40% of HCC patients exhibit normal AFP levels, including very early HC
Externí odkaz:
https://doaj.org/article/2af793b28b39442a8e97a020666c6a1d
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0211795 (2019)
Recent advance in the direct-acting antivirals (DAAs) offers the potentials to eradicate hepatitis C virus (HCV) worldwide and makes universal screening more urgent. A point-of-care (POC) oral anti-HCV assay, the Fortune assay, was developed and its
Externí odkaz:
https://doaj.org/article/776a20e1d65a4f5bbffea7d3368dd63a
Autor:
Su-Jun Zheng, Feng Qu, Jun-Feng Li, Jing Zhao, Jing-Yun Zhang, Mei Liu, Feng Ren, Yu Chen, Jin-Lan Zhang, Zhong-Ping Duan
Publikováno v:
International Journal of Infectious Diseases, Vol 33, Iss C, Pp 149-155 (2015)
Objective: To explore the relation between serum sphingolipids and hepatic injury in chronic HBV infection. Methods: A cohort of participants including 48 healthy persons, 103 chronic HBV-infected patients containing chronic hepatitis B (CHB) and HBV
Externí odkaz:
https://doaj.org/article/e51c875ace4a4a7fa43e33d35c95af72
Autor:
Jun-Feng Li, Shuang Liu, Feng Ren, Mei Liu, Hui-Li Wu, Yu Chen, Huai-Bin Zou, Li Bai, Ying Li, Su-Jun Zheng, Zhong-Ping Duan
Publikováno v:
International Journal of Infectious Diseases, Vol 27, Iss C, Pp 49-53 (2014)
Objectives: To evaluate the progression of fibrosis and factors influencing this in interferon (IFN) treatment-naive Chinese plasma donors infected with hepatitis C virus (HCV) for approximately 20 years. Methods: From July 2010 to June 2011, we inve
Externí odkaz:
https://doaj.org/article/7351a64023ff4380a33c256871c91913
Autor:
Guo-Feng Chen, Lai Wei, Jing Chen, Zhong-Ping Duan, Xiao-Guang Dou, Qing Xie, Wen-Hong Zhang, Lun-Gen Lu, Jian-Gao Fan, Jun Cheng, Gui-Qiang Wang, Hong Ren, Jiu-Ping Wang, Xing-Xiang Yang, Zhan-Sheng Jia, Qing-Chun Fu, Xiao-Jin Wang, Jia Shang, Yue-Xin Zhang, Ying Han, Ning Du, Qing Shao, Dong Ji, Fan Li, Bing Li, Jia-Liang Liu, Xiao-Xia Niu, Cheng Wang, Vanessa Wu, April Wong, Yu-Dong Wang, Jin-Lin Hou, Ji-Dong Jia, Hui Zhuang, George Lau
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0155934 (2016)
BACKGROUND:Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated cost-effectiveness
Externí odkaz:
https://doaj.org/article/55312918acea4da8a5f35778cff06e88
Autor:
Mei Liu, Su-jun Zheng, Yu Chen, Ning Li, Peng-fei Ren, Li-ping Dai, Zhong-ping Duan, Jian-Ying Zhang
Publikováno v:
Journal of Immunology Research, Vol 2014 (2014)
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Although new therapeutic strategies have been continuously developed and applied to clinical treatment for HCC, the prognosis is still very poor. Thus, early detection of H
Externí odkaz:
https://doaj.org/article/2743ac49eb7440edae8bb9d6de13238d
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e109652 (2014)
BACKGROUND: Hepatitis B virus (HBV) infection is a significant clinical and financial burden for chronic hepatitis B (CHB) patients. In Beijing, China, partial reimbursement on antiviral agents was first implemented for the treatment of CHB patients
Externí odkaz:
https://doaj.org/article/2e54d1516aee46af994a0600bc66d134
Autor:
Lu Li, Yi-Rong Liu, Shan Gao, Jun-Feng Li, Shan-Shan Li, Dan-Dan Zhang, Shuang Liu, Li Bai, Su-Jun Zheng, Zhong-Ping Duan, Min Qi, Yu Chen
Publikováno v:
Journal of Immunology Research, Vol 2014 (2014)
This study aimed to investigate the role of 5-lipoxygenase (5-LO) in acute liver failure (ALF) and changes in macrophage activation by blocking it. ALF was induced in rats by administration of D-galactosamine (D-GalN)/lipopolysaccharide (LPS). Rats w
Externí odkaz:
https://doaj.org/article/0750b378cb10453fb164af2beed868d5